Key Highlights

  • Caris Life Sciences shares fell 15.50% pre-market today to $28.07, from a prior close of $33.22.
  • Third-quarter Revenue rose 27% to $275.4 million, ahead of the $255.4 million estimate.
  • Clinical cases grew 21% to roughly 61,500, the third straight quarter of faster growth.
  • Free Cash Flow was negative $39.7 million, while operating expenses climbed 42% to $163 million.
  • Full-year revenue guidance rose to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion.

Caris Life Sciences (NASDAQ:CAI) shares dropped sharply in pre-market activity today after the company reported third-quarter results that topped revenue and Earnings estimates and lifted its full-year outlook. The stock changed hands at $28.07, down 15.50% from Wednesday's close of $33.22, which followed a 1.13% gain in the regular session.

Caris is an Irving, Texas-based precision oncology company that applies artificial intelligence to molecular data. It combines whole exome, whole transcriptome and whole genome sequencing with Machine Learning to build a large clinico-genomic database, which powers its tissue-based MI Profile and the blood-based Caris Assure.

The sell-off centers on spending and cash flow rather than the top line. Operating expenses rose 42% to $163 million, Net Income fell to $15.3 million from $24.3 million a year earlier, and free cash flow was negative $39.7 million after a planned inventory buildup.

Revenue Beat and Raised Outlook Meet a Higher Spending Plan

Third-quarter revenue reached $275.4 million, up 27% year over year and about 45% on a pro forma basis for prior-year true-ups. Analysts had expected $255.4 million. Clinical cases rose 21% to roughly 61,500, and blended average selling price was $4,272, with the base price near $3,990, up 19%. Gross Margin was 66%, and adjusted earnings of $0.05 per share beat the $0.03 estimate.

Full-year revenue is now expected at $1.04 billion to $1.05 billion, or 28% to 29% growth. Fourth-quarter revenue is guided to $285 million to $295 million, made up of about $265 million from molecular profiling and $20 million to $30 million from pharma, on roughly 65,000 clinical cases. Full-year operating expenses are now expected near $620 million, up from $600 million, with positive adjusted EBITDA.

A Higher 2027 Reimbursement Rate and a December MRD Launch Shape the Setup

Caris Assure therapy response monitoring launched this quarter, and Caris Confirm, a whole genome minimal residual disease test, launches in December. A MolDX submission is planned in the coming months after publication of the trial data. The proposed 2027 clinical lab fee schedule raises the Caris Assure rate to $5,250 from $3,650, effective January 1, with the benefit expected mainly in the first and second quarters.

The sales force grew to 325 from 290 last quarter, with more hiring planned. In multi-cancer early detection, the Achieve 1 study showed 99.2% specificity and 60.3% sensitivity in stage 1 and 2 cancers.

Cash of $769 Million Backs a Premium Valuation

Caris ended the quarter with $769 million in cash and investments. The company carries a market Capitalization of about $9.39 billion, a forward price-to-earnings ratio of 107.82 and a trailing ratio of 101.93, on Earnings Per Share of $0.36. Its 52-week range runs from $14.19 to $36.50. A $100 million share repurchase authorization is also in place.

Adjusted EBITDA was $44.4 million, the sixth straight positive quarter.

December MRD Launch and January Pricing Reset Are the Next Markers

The next checkpoints are the Caris Confirm launch in December, the January 1 fee schedule change and fourth-quarter case Volume near 65,000.